BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 29222348)

  • 1. Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
    Li H; Wu J; Zhu L; Sha L; Yang S; Wei J; Ji L; Tang X; Mao K; Cao L; Wei N; Xie W; Yang Z
    Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29222348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cAMP/PKA signaling pathway contributes to neuronal apoptosis via regulating IDE expression in a mixed model of type 2 diabetes and Alzheimer's disease.
    Li H; Yang S; Wu J; Ji L; Zhu L; Cao L; Huang J; Jiang Q; Wei J; Liu M; Mao K; Wei N; Xie W; Yang Z
    J Cell Biochem; 2018 Feb; 119(2):1616-1626. PubMed ID: 28771808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
    Farris W; Mansourian S; Chang Y; Lindsley L; Eckman EA; Frosch MP; Eckman CB; Tanzi RE; Selkoe DJ; Guenette S
    Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4162-7. PubMed ID: 12634421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ginsenoside Rg1 decreases Aβ(1-42) level by upregulating PPARγ and IDE expression in the hippocampus of a rat model of Alzheimer's disease.
    Quan Q; Wang J; Li X; Wang Y
    PLoS One; 2013; 8(3):e59155. PubMed ID: 23520555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
    Tang WJ
    Trends Endocrinol Metab; 2016 Jan; 27(1):24-34. PubMed ID: 26651592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
    Du J; Zhang L; Liu S; Zhang C; Huang X; Li J; Zhao N; Wang Z
    Biochem Biophys Res Commun; 2009 Jun; 383(4):485-90. PubMed ID: 19383491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein.
    Farris W; Mansourian S; Leissring MA; Eckman EA; Bertram L; Eckman CB; Tanzi RE; Selkoe DJ
    Am J Pathol; 2004 Apr; 164(4):1425-34. PubMed ID: 15039230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease.
    Vandal M; White PJ; Chevrier G; Tremblay C; St-Amour I; Planel E; Marette A; Calon F
    FASEB J; 2015 Oct; 29(10):4273-84. PubMed ID: 26108977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interplay between Alzheimer's disease and global glucose metabolism revealed by the metabolic profile alterations of pancreatic tissue and serum in APP/PS1 transgenic mice.
    Liu X; Wang W; Chen HL; Zhang HY; Zhang NX
    Acta Pharmacol Sin; 2019 Oct; 40(10):1259-1268. PubMed ID: 31089202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Aβ production prompts the onset of glucose intolerance and insulin resistance.
    Jiménez-Palomares M; Ramos-Rodríguez JJ; López-Acosta JF; Pacheco-Herrero M; Lechuga-Sancho AM; Perdomo G; García-Alloza M; Cózar-Castellano I
    Am J Physiol Endocrinol Metab; 2012 Jun; 302(11):E1373-80. PubMed ID: 22414803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
    Qiu WQ; Folstein MF
    Neurobiol Aging; 2006 Feb; 27(2):190-8. PubMed ID: 16399206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer's APP/PSEN1 mice by gene targeting of diabetes/Alzheimer's-related Sorcs1.
    Knight EM; Ruiz HH; Kim SH; Harte JC; Hsieh W; Glabe C; Klein WL; Attie AD; Buettner C; Ehrlich ME; Gandy S
    Acta Neuropathol Commun; 2016 Feb; 4():16. PubMed ID: 26916443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice.
    Plaschke K; Kopitz J; Siegelin M; Schliebs R; Salkovic-Petrisic M; Riederer P; Hoyer S
    J Alzheimers Dis; 2010; 19(2):691-704. PubMed ID: 20110613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
    Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
    J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ageing and experimental diabetes on insulin-degrading enzyme expression in male rat tissues.
    Kochkina EG; Plesneva SA; Vasilev DS; Zhuravin IA; Turner AJ; Nalivaeva NN
    Biogerontology; 2015 Aug; 16(4):473-84. PubMed ID: 25792373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice.
    Pedersen WA; McMillan PJ; Kulstad JJ; Leverenz JB; Craft S; Haynatzki GR
    Exp Neurol; 2006 Jun; 199(2):265-73. PubMed ID: 16515786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice.
    Yin K; Jin J; Zhu X; Yu L; Wang S; Qian L; Han L; Xu Y
    Neurol Res; 2017 Oct; 39(10):885-894. PubMed ID: 28743230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose tolerance and insulin sensitivity are impaired in APP/PS1 transgenic mice prior to amyloid plaque pathogenesis and cognitive decline.
    Macklin L; Griffith CM; Cai Y; Rose GM; Yan XX; Patrylo PR
    Exp Gerontol; 2017 Feb; 88():9-18. PubMed ID: 28025127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease.
    Kawahara K; Suenobu M; Ohtsuka H; Kuniyasu A; Sugimoto Y; Nakagomi M; Fukasawa H; Shudo K; Nakayama H
    J Alzheimers Dis; 2014; 42(2):587-605. PubMed ID: 24916544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 and DPP4 inhibitors improve Alzheimer's disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model.
    Sim AY; Choi DH; Kim JY; Kim ER; Goh AR; Lee YH; Lee JE
    Biomed Pharmacother; 2023 Dec; 168():115755. PubMed ID: 37871560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.